Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Read more
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US Read more
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology Read more
Lilly’s Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Read more
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics Read more
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Read more
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Read more
Datopotamab Deruxtecan BLA Submitted for Accelerated Approval in the U.S. for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Read more